Trial Profile
Clinical Pilot Study of Autologous Stem Cell Transplantation of Cluster of Differentiation 34 Positive (CD34+) Cells Engineered to Express Alpha-Galactosidase A in Patients With Fabry Disease
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 08 Dec 2021
Price :
$35
*
At a glance
- Drugs AVR RD 01 (Primary)
- Indications Fabry's disease
- Focus Adverse reactions; First in man
- Acronyms FACTs
- 24 Nov 2021 Results published in an AVROBIO Media Release.
- 24 Nov 2021 According to an AVROBIO media release, data presented at the 14th International Congress of Inborn Errors of Metabolism (ICIEM).
- 04 Nov 2021 According to a AVROBIO media release, data from this trial will be presented at the 18th Annual WORLDSymposium in February 2022.